Abstract

Halofantrine (Halfan – SKB) is a new phenanthrene antimalarial introduced last year for the oral treatment of patients with falciparum and vivax malaria. The data sheet states that it is especially useful for the treatment of patients “likely to be infected with chloroquine or multi-drug-resistant strains of malaria”. We have previously discussed drug treatments for choroquine-resistant malaria.¹ Where does halofantrine fit in?